Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer-Reference-Cited by-同舟云学术

Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer

Published:2011-11-21 Issue:12 Volume:26 Page:2827-2833
ISSN:0884-0431
Container-title:Journal of Bone and Mineral Research
language:en
Short-container-title:J Bone Miner Res

Author:

Smith Matthew R,Saad Fred,Egerdie Blair,Sieber Paul,Tammela Teuvo LJ,Leder Benjamin Z,Ke Chunlei,Goessl Carsten

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jbmr.492/fullpdf

Reference21 articles.

1. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy;Israeli;J Urol.,2008

2. Treatment-related osteoporosis in men with prostate cancer;Smith;Clin Cancer Res.,2006

3. Biochemical markers of bone turnover, hip bone loss and fracture in older men: the MrOS Study;Bauer;J Bone Miner Res.,2009

4. Bone turnover markers: understanding their value in clinical trials and clinical practice;Civitelli;Osteoporos Int.,2009

5. Relationships between sex steroids and markers of bone turnover in prostate cancer males with and without androgen deprivation therapy. ASBMR 31st Annual Meeting, Denver, CO, USA, 2009;Mariela;J Bone Miner Res.

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biochemical markers of bone turnover in osteoporosis;Marcus and Feldman's Osteoporosis;2021

2. Denosumab for cancer-related bone loss;Expert Opinion on Biological Therapy;2020-09-09

3. Integrating the immune microenvironment of prostate cancer induced bone disease;Molecular Carcinogenesis;2020-03-31

4. How Prostate Cancer Cells Use Strategy Instead of Brute Force to Achieve Metastasis;Cancers;2019-12-03

5. Tumor Cell Dormancy—a Hallmark of Metastatic Growth and Disease Recurrence in Bone;Current Molecular Biology Reports;2018-03-21